drugset / Trial / NCT00100256
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum dose that is safely tolerated of the experimental drug Rhenium Re 188 P2045. This will be done by first treating patients at relatively low doses of Rhenium Re 188 P2045, observing them closely to assure that there are no bad side effects, then increasing the dose when we are confident that it is safe to do so.
Timeline
- Start
- 2004-01
- Primary completion
- 2009-06-20
- Completion
- 2025-04-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rhenium Re 188 P2045 | Unknown | — | Other |